Seoul
Chief MD, Gangnam
Duk-ha Kim
The trust our patients have placed in this clinic was built on conviction and principle. We intend to hold to both, unchanged, through the next hundred years.
Human-tissue injectable guide
Elravie Re2O
Elravie Re2O is an injectable product that its own manufacturer files under a Human tissue category — separate from Medical Device or Cosmetic — and describes as freeze-dried human tissue named ADM 150mg. That classification, not a filler comparison, is the starting point for reading everything else about it: its composition, its relationship to the similarly named Elravie Balance, and the clinical trial evidence behind it.
- Manufacturer’s own category
- Human tissue — separate from Medical Device and Cosmetic; listed product name ADM 150mg (Humedix product page)
- Storage and form
- Freeze-dried human tissue, stored at room temperature (1 to 30°C)
- Raw material manufacturer
- L&C Bio — particulated acellular dermal matrix, raw material Skin
- Comparator product, same brand
- Elravie Balance — Disposable medical device; hyaluronic acid 20 mg/mL plus 0.3% lidocaine
What is Elravie Re2O?
Elravie Re2O is an injectable product in the Elravie line sold by Humedix, with its raw material manufactured by L&C Bio. On its own product page, Humedix does not list it as a medical device or a cosmetic — the listed category is “Human tissue (transplanted to ensure the integrity of the body and restore physiological functions),” and the listed name is “ADM 150mg.” The same page states that the product “is freeze-dried human tissue and must be stored at room temperature (1 to 30°C).” Those three details — the category, the name, and the storage instruction — come directly from the manufacturer’s own listing, and they are the starting point for everything else on this page.
Sources: Humedix — Elravie Re2O product page (category: human tissue, ADM 150 mg)L&C Bio — Re2O particulated acellular dermal matrix product page
What does “human tissue” mean as a product category?
It means the manufacturer itself is not filing this product under the categories most injectables use. Humedix’s own product page places Elravie Re2O in a category called Human tissue, separate from a Medical Device listing or a Cosmetic listing elsewhere on the same kind of catalogue page. That distinction is the manufacturer’s own classification, not a description this page has assigned — and it is worth taking literally: a product filed as human tissue is not automatically covered by the rules, expectations, or evidence base that apply to a device-classified filler or a cosmetic-classified skincare product.
Sources: Humedix — Elravie Re2O product page (category: human tissue, ADM 150 mg)
Is Elravie Re2O a hyaluronic-acid filler?
No — nothing in the sources cited on this page describes Elravie Re2O as a hyaluronic-acid product or as a filler. L&C Bio’s own product page names it a “particulated acellular dermal matrix,” manufactured from human tissue with skin as the raw material. That is a different material class from a cross-linked hyaluronic-acid gel, and this page does not use filler language — cross-linking, gel, or duration claims — to describe it, because none of the four sources used here support that description.
Sources: L&C Bio — Re2O particulated acellular dermal matrix product pageHumedix — Elravie Re2O product page (category: human tissue, ADM 150 mg)
Where does the raw material come from?
It comes from L&C Bio, a company separate from Humedix that manufactures the raw material used in Elravie Re2O. L&C Bio’s own product page describes Re2O as a particulated acellular dermal matrix — an allogeneic (donor-derived) dermal tissue that has been processed to remove cells and broken into particulated form, with skin as the raw material. Humedix is the company whose product page lists Elravie Re2O for sale and gives it the Human tissue category and the ADM 150mg name; L&C Bio is the manufacturer of the underlying tissue material that goes into it. Both companies’ own pages are cited here, and neither is treated as a substitute for the other.
Sources: L&C Bio — Re2O particulated acellular dermal matrix product pageHumedix — Elravie Re2O product page (category: human tissue, ADM 150 mg)
What does the published composition of the injected material show?
A peer-reviewed trial that tested this material reported four figures for its composition: collagen at roughly 80%, elastin at roughly 3%, sulfated glycosaminoglycan (sGAG) at roughly 0.4%, and residual DNA below 50 nanograms per milligram. Collagen and elastin are structural proteins normally found in dermal tissue; sGAG is a class of molecule associated with tissue hydration and structure; residual DNA is a processing-quality figure — acellular tissue processing is meant to remove cellular material, and a low residual-DNA figure is one way a study reports how thoroughly that was done. These numbers come from the trial’s own characterisation of the material used in that specific study, not from a public specification sheet, and this page does not extend them beyond what the trial reported.
How is Elravie Re2O different from Elravie Balance?
They share a brand name and very little else. Humedix’s own product page for Elravie Balance lists it as a Disposable medical device, with a composition of hyaluronic acid at 20 mg/mL plus 0.3% lidocaine, and describes its effect as temporary improvement of facial wrinkles. Elravie Re2O, on the same manufacturer’s site, is listed under the Human tissue category with the name ADM 150mg — a different material, a different manufacturing origin (L&C Bio’s particulated acellular dermal matrix rather than a hyaluronic-acid gel), and a different classification on the page itself. In the clinical trial cited on this page, the two products were even used together in one treatment mixture and separately as the comparison side — a design that only works because they are genuinely two different materials, not two names for the same thing.
Sources: Humedix — Elravie Balance 1.5 mL product page (hyaluronic acid 20 mg/mL, 0.3% lidocaine)Humedix — Elravie Re2O product page (category: human tissue, ADM 150 mg)
Does sharing the Elravie name mean the two products share a category?
No. This is the point the rest of this page keeps returning to: a shared brand name is a marketing decision, and it does not override the classification each product carries on the manufacturer’s own page. Elravie Balance is listed as a Disposable medical device with a hyaluronic-acid and lidocaine composition; Elravie Re2O is listed under Human tissue with a particulated-acellular-dermal-matrix origin. Treat “Elravie” as identifying a product family, and treat the rest of the name — Re2O or Balance — as the part that tells you which material, which category, and which product page actually applies.
Sources: Humedix — Elravie Re2O product page (category: human tissue, ADM 150 mg)Humedix — Elravie Balance 1.5 mL product page (hyaluronic acid 20 mg/mL, 0.3% lidocaine)L&C Bio — Re2O particulated acellular dermal matrix product page
What was the design of the clinical trial behind this evidence?
A randomised, split-face, double-blinded trial, published in the International Journal of Molecular Sciences (2026;27(5):2193). It enrolled 20 participants — 13 women and 7 men — with a mean age of 54.7 years (standard deviation 9.246). Split-face means each participant received one treatment on one side of the face and a different treatment on the other side of the same face, which lets the study compare two treatments within the same person rather than between two separate groups. Double-blinded means neither the participant nor the assessor was told which side received which treatment during evaluation. This page reports the design as published; it does not add an efficacy conclusion beyond what the design itself supports.
What exactly was injected, and in what amount?
On the treatment side of each participant’s face, the trial used a mixture of 150 mg of particulated human acellular dermal matrix (phADM), 1.5 mL of Elravie Balance, 2.1 mL of saline, and 0.4 mL of lidocaine, combined into a total volume of 4.0 mL — and 1.5 mL of that combined mixture was the amount actually injected, which the paper calculates as roughly 56.25 mg of phADM and 7.5 mg of hyaluronic acid in the injected volume. The comparison side of the same participant’s face received Elravie Balance alone, with no phADM added. Reporting the diluted, per-injection amount rather than the full batch figure is the more accurate way to describe what a participant’s tissue actually received in this study.
What outcomes did the trial measure?
The trial followed participants from baseline through weeks 1, 4, 8, 12, 16 and 20, measuring skin density and volume, transepidermal water loss (TEWL) and hydration, skin elasticity, wrinkle depth, pore area, pigmentation and erythema, and two rating scales — the Global Aesthetic Improvement Scale (GAIS) and a comparison-style scar/skin scale (ACSS). That is a broad measurement set covering structural, functional and visual measures of the skin, plus assessor and patient rating scales, tracked across roughly five months of follow-up. This page lists what was measured; it does not restate isolated improvement percentages here, because a single percentage figure from a 20-person split-face study is easy to misread without the full context of each measure.
How long does the effect last?
The one published trial followed participants from baseline through week 20 — roughly five months — tracking density, volume, elasticity and the other measures listed above; that is the longest timepoint in the source, not a stated duration of effect. On the comparison side of each face the study injected Elravie Balance alone, so what the trial can show is a difference tied to adding phADM on top of an active hyaluronic-acid treatment, over that five-month window — not a treatment-versus-no-treatment result, and not a result beyond week 20 in either arm. The trial’s small sample (20 participants) and the disclosed advisor relationship between one author and the raw-material manufacturer are further reasons not to read that window as a guaranteed duration. Because Elravie Re2O itself is reported as a particulated acellular dermal matrix — mostly collagen and elastin rather than a cross-linked hyaluronic-acid gel — how a change from it holds up is more a question of that material’s composition and how the body incorporates or resorbs it than a single trial figure can settle. Ask the clinic what timepoint its own follow-up covers, what exactly is mixed into the injected volume, and how it decides when to repeat treatment.
What did the trial report about safety?
The paper states, in its own words, that “no serious adverse events were observed during the clinical study.” That is the full extent of the safety statement this page can cite from the source, and it describes what happened within a 20-person trial followed for roughly five months — it is not a long-term safety record, and it is not a statement covering the wider population of people who might receive this product outside a clinical trial setting. Human-tissue-derived injectables are a category where longer-term safety data matters, and this page does not have a longer-term dataset to cite for Elravie Re2O beyond this one study.
What are the limits of this trial’s evidence?
Three limits are worth naming together. The sample was small — 20 participants — which limits how confidently any single result generalises. The comparison side of each participant’s face did not go untreated; it received Elravie Balance, an active hyaluronic-acid product from the same manufacturer, so the trial measures a difference between two treatments rather than a difference between treatment and no treatment at all — meaning the results describe a relative comparison, not a stand-alone measure of effectiveness. And the paper discloses a financial and professional relationship between one of its authors and the product’s manufacturer, described in the next section. None of these limits mean the trial is invalid; they mean its findings should be read as exactly what a 20-person, actively-controlled, conflict-disclosed study can support — not more than that.
Is there a disclosed conflict of interest in the supporting study?
Yes, and the paper states it directly: one of the authors “served as an advisor for the development of the product Elravie Re2O at L&C Bio Co., Ltd.” — the same company that manufactures the raw material used in the product being studied. The paper also states that the study received no external funding. Disclosing this relationship is standard scientific practice and does not by itself mean the results are wrong, but it is a detail worth weighing alongside the small sample size and the active-comparator design when deciding how much weight to place on the trial’s findings.
What does the trial paper say about regulatory oversight?
The trial paper places its subject within a specific regulatory setting: it describes particulated human acellular dermal matrix products of this kind as “regulated by the MFDS of Korea” — Korea’s Ministry of Food and Drug Safety. That sentence appears in a paper about a treatment carried out in Korea, alongside the trial’s own description of its randomised, split-face, double-blinded design and its 20-person sample. This page quotes that sentence exactly as the paper wrote it.
How can you confirm which product is actually being used?
Ask for the full product name before treatment, not just the brand name — “Elravie” alone does not tell you whether Re2O or Balance is planned, and those two products have different categories and different compositions. Ask to see the outer box and lot number before it is opened. If the plan involves mixing Elravie Re2O with another product, as the cited trial mixed it with Elravie Balance, ask what is being added and in what amount, since the diluted amount actually injected is what matters, not the raw figure on the label. And if a specific approval or permit number is quoted to you, ask to see it on the packaging or in the manufacturer’s own material before relying on it.
Sources: Humedix — Elravie Re2O product page (category: human tissue, ADM 150 mg)Humedix — Elravie Balance 1.5 mL product page (hyaluronic acid 20 mg/mL, 0.3% lidocaine)L&C Bio — Re2O particulated acellular dermal matrix product page
Are Elravie Re2O, Elravie Balance, and a “skin booster” injection the same thing?
They are three different kinds of thing: one named human-tissue product, one named hyaluronic-acid device carrying the same brand name, and one spoken category with no fixed meaning. Compare what each one actually refers to before comparing anything else.
| What you might be offered | What it actually refers to | Category and composition on the manufacturer’s own page | Confirm before booking |
|---|---|---|---|
| Elravie Re2O | A named human-tissue injectable manufactured from a particulated acellular dermal matrix | Listed as Human tissue, product name ADM 150mg; raw material by L&C Bio | The full product name, the outer box and lot number, and what it is mixed with, if anything |
| Elravie Balance | A named hyaluronic-acid injectable sold under the same brand name | Listed as a Disposable medical device; hyaluronic acid 20 mg/mL plus 0.3% lidocaine | That this is a different product from Re2O even though the brand name is shared |
| Skin booster / water-glow injection as a spoken category | Marketplace shorthand covering many different injectables | None — the manufacturer’s category and composition attach to a named product, never to a spoken phrase | Which named product is actually planned, before price or session count |
This table maps what the words refer to, using each manufacturer’s own product page. It is not a ranking, not a recommendation, and it does not describe how any individual will respond to treatment.
Sources: Humedix — Elravie Re2O product page (category: human tissue, ADM 150 mg)Humedix — Elravie Balance 1.5 mL product page (hyaluronic acid 20 mg/mL, 0.3% lidocaine)L&C Bio — Re2O particulated acellular dermal matrix product page
Medical care at Abijou
Care is provided by the medical team at the branch you select. These clinicians lead the three branches linked from this guide; confirm the doctor assigned to your visit with that branch.
Chief MD, Myeongdong
Cheol-su Yoon
I want to be thinking about how the patient feels right up to the last moment of the procedure.
Chief MD, Hongdae
Jae-wook Kim
I will give my best with the attentiveness to catch even the smallest change.
Listed branch medical team — not a medical-review byline for this article.
Frequently asked questions
Is Elravie Re2O a hyaluronic-acid filler?
No. L&C Bio’s own product page describes it as a particulated acellular dermal matrix made from human tissue, and Humedix’s own listing places it under a Human tissue category rather than describing it with hyaluronic-acid or filler terminology. None of the four sources used on this page call it a filler, a gel, or a cross-linked hyaluronic-acid product, so this page does not either.
What does “human tissue” mean as a product category?
It means the manufacturer itself is not filing Elravie Re2O under the Medical Device or Cosmetic categories used for other products. Humedix’s own product page names the category “Human tissue (transplanted to ensure the integrity of the body and restore physiological functions)” and gives the product name as “ADM 150mg.” That is the manufacturer’s own classification, taken from its own listing.
Where does the raw material for Elravie Re2O come from?
From L&C Bio, whose own product page describes the material as a particulated acellular dermal matrix — donor-derived dermal tissue, processed to remove cells and broken into particulated form, using skin as the raw material. Humedix is the company that lists and sells the finished product as Elravie Re2O; L&C Bio manufactures the underlying tissue material that goes into it.
What is the difference between Elravie Re2O and Elravie Balance?
They are different products that happen to share a brand name. Elravie Balance is listed by Humedix as a Disposable medical device containing hyaluronic acid at 20 mg/mL plus 0.3% lidocaine, described for temporary improvement of facial wrinkles. Elravie Re2O is listed under the Human tissue category, named ADM 150mg, and manufactured from L&C Bio’s particulated acellular dermal matrix — a different material with a different classification.
Does the shared “Elravie” name mean the two products are in the same category?
No. A shared brand name is a marketing choice, not a regulatory or material classification. Elravie Balance carries the Disposable medical device listing with a hyaluronic-acid composition, while Elravie Re2O carries the Human tissue listing with a particulated-acellular-dermal-matrix origin — two different classifications on the same manufacturer’s own pages.
What did the clinical trial supporting Elravie Re2O actually test?
A randomised, split-face, double-blinded trial in 20 participants, published in the International Journal of Molecular Sciences (2026;27(5):2193). Each participant received a mixture containing particulated human acellular dermal matrix (phADM) plus Elravie Balance on one side of the face, and Elravie Balance alone on the other side, with outcomes tracked from baseline through week 20.
How much of the product was actually injected in the trial?
The treatment mixture combined 150 mg of phADM, 1.5 mL of Elravie Balance, 2.1 mL of saline and 0.4 mL of lidocaine into a 4.0 mL total, and 1.5 mL of that mixture was the volume actually injected — roughly 56.25 mg of phADM and 7.5 mg of hyaluronic acid, by the paper’s own calculation. The comparison side received 1.5 mL of Elravie Balance alone.
What did the trial measure, and did it report any serious side effects?
It measured skin density and volume, TEWL and hydration, elasticity, wrinkle depth, pore area, pigmentation and erythema, plus GAIS and ACSS ratings, at baseline and weeks 1, 4, 8, 12, 16 and 20. On safety, the paper states that no serious adverse events were observed during the clinical study — a statement covering this one 20-person trial, not a long-term safety record.
How reliable is this trial evidence?
It is evidence from a small, actively-controlled study, and both of those facts limit how far it generalises. Twenty participants is a small sample, and the comparison side of each face received an active hyaluronic-acid product, Elravie Balance, rather than no treatment at all — so the trial measures a difference between two treatments, not treatment versus untreated skin, and the results should be read as a relative comparison rather than a stand-alone effectiveness figure.
Is there a conflict of interest in the study behind Elravie Re2O?
Yes. The paper discloses that one author “served as an advisor for the development of the product Elravie Re2O at L&C Bio Co., Ltd.,” the same company that manufactures the material’s raw form, and states that the study received no external funding. That disclosure does not by itself invalidate the findings, but it is worth weighing alongside the small sample size when judging how much the trial supports.
What does the trial paper say about regulatory oversight for this material?
The paper describes particulated human acellular dermal matrix products of this kind as “regulated by the MFDS of Korea” — Korea’s Ministry of Food and Drug Safety. That sentence sits in the paper alongside its description of the randomised, split-face, double-blinded trial design and its 20-person sample, and this page quotes it exactly as written, in the same scope the paper gives it.
Is Elravie Re2O the same as a hyaluronic-acid skin booster or “water-glow” injection?
No. Those are spoken category names covering many different injectables, with no fixed classification attached to them. Elravie Re2O is a specifically named product listed by its manufacturer under a Human tissue category, made from a particulated acellular dermal matrix rather than hyaluronic acid — a different material from what most products sold under a “skin booster” or “water-glow” label contain.
How can I confirm which product is actually being used in my treatment?
Ask for the full product name — Elravie Re2O specifically, not just “Elravie” — since the brand name alone does not distinguish it from Elravie Balance. Ask to see the outer box and lot number before it is opened, and if it is being mixed with another product, ask what is being added and in what amount, since the diluted, per-injection amount is what your tissue actually receives.
Who should ask more questions before booking this treatment?
Anyone offered Elravie Re2O as if it were interchangeable with a hyaluronic-acid filler or skin booster, since it is manufactured and categorised differently. Anyone quoted a specific approval or permit number, since it is worth checking that number directly against the product packaging or the manufacturer’s own material rather than taking it at face value. And anyone comparing Elravie Re2O to Elravie Balance by brand name alone, since the two carry different classifications and different compositions on the manufacturer’s own pages.
How Abijou works
We started in Gangnam in 2006 and the network now runs 17 branches across Korea. The line we work to is skin transformation woven into everyday life — care you can keep up with, rather than one dramatic change.
- Across the 17 branches in Seoul, Gyeonggi, Incheon and Busan: over 1,000 medical professionals and more than 350 certified medical devices
- Authentic products only, in appropriate amounts — the treatment is fitted to the condition, not to a package
- Prices are quoted from each branch’s published price list as it stands
Contact and location
- Phone
- 1544-0377
Free Consultation
Booking happens at the branch
There is no inquiry form on this page. Once you have picked a branch above, open that branch’s site or the official reservation center and choose a time yourself.
- No deposit and no online prepayment — everything is paid at the visit
- Per-treatment prices are published for each branch on the official reservation center
- English, Japanese and Chinese are supported alongside Korean